T. Rowe Price Investment Management
PCVX icon

T. Rowe Price Investment Management’s Vaxcyte PCVX Stock Holding History

T. Rowe Price Investment Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$705M Buy
12,126,017
+829,684
+7% +$45M 0.49% 53
2025
Q4 		$521M Buy
11,296,333
+2,981,038
+36% +$133M 0.33% 79
2025
Q3 		$300M Buy
8,315,295
+2,314,171
+39% +$76.7M 0.18% 129
2025
Q2 		$195M Buy
6,001,124
+3,298,433
+122% +$108M 0.12% 181
2025
Q1 		$102M Sell
2,702,691
-158,026
-6% -$12.6M 0.07% 276
2024
Q4 		$234M Sell
2,860,717
-1,193,111
-29% -$118M 0.14% 158
2024
Q3 		$463M Buy
4,053,828
+31,239
+0.8% +$2.82M 0.28% 95
2024
Q2 		$304M Buy
4,022,589
+469,622
+13% +$32M 0.19% 129
2024
Q1 		$243M Buy
3,552,967
+2,306,926
+185% +$160M 0.15% 163
2023
Q4 		$78.3M Buy
1,246,041
+41,413
+3% +$2.15M 0.05% 316
2023
Q3 		$61.4M Buy
1,204,628
+61,710
+5% +$3.04M 0.04% 338
2023
Q2 		$57.1M Buy
1,142,918
+409,011
+56% +$19.4M 0.04% 360
2023
Q1 		$27.5M Buy
733,907
+222,471
+43% +$9.44M 0.02% 438
2022
Q4 		$24.5M Buy
+511,436
New +$20.1M 0.02% 438

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Investment Management's PCVX Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its Vaxcyte (PCVX) stake by 7.3% in Q1 2026, buying an estimated $45M and bringing the position to 12,126,017 shares worth $705M. The position accounts for 0.49% of the portfolio, ranked #53.

T. Rowe Price Investment Management first reported a position in PCVX in Q4 2022 and has held it in 14 quarters since. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • T. Rowe Price Investment Management held 12,126,017 shares of Vaxcyte worth $705M as of Q1 2026.
  • T. Rowe Price Investment Management bought 829,684 Vaxcyte shares in Q1 2026, an estimated $45M.
  • Vaxcyte made up 0.49% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #53 holding.
  • T. Rowe Price Investment Management first reported a position in Vaxcyte in Q4 2022 and has held it in 14 quarters since.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.